ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10964	Companies
240023	Keywords
168772	Articles
129130	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 06/03/2026 at 20:29, 3 months 7 days ago

Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting
OSE Immunotherapeutics SA announces Annual General Meeting on June 24, 2026, with procedures for obtaining preparatory documents. Meeting details and documents available on company website

Annual General Meeting Shareholders French Commercial Code Preparatory Documents OSE Immunotherapeutics
PRESS RELEASE

published on 06/03/2026 at 20:29, 3 months 7 days ago

Assemblée Générale Mixte du 24 juin 2026 Modalités de mise à disposition des documents préparatoires à l’Assemblée
Annonce de l'Assemblée Générale Mixte d'OSE Immunotherapeutics le 24 juin 2026. Modalités de consultation des documents préparatoires disponibles en ligne et lors de l'Assemblée

Actionnaires Documents Préparatoires Immuno-oncologie Assemblée Générale Mixte OSE Immunotherapeutics
BRIEF

published on 06/03/2026 at 20:24, 3 months 7 days ago

OSE Immunotherapeutics : Publication des résultats financiers 2025

Document D'Enregistrement Universel OSE Immunotherapeutics Stratégie De Financement Résultats Financiers 2025 Financement IRIS
BRIEF

published on 06/03/2026 at 20:24, 3 months 7 days ago

OSE Immunotherapeutics: Publication of 2025 Financial Results

Universal Registration Document OSE Immunotherapeutics Funding Strategy 2025 Financial Results IRIS Funding
BRIEF

published on 06/03/2026 at 20:24, 3 months 7 days ago

OSE Immunotherapeutics Reports 2025 Financial Results and Universal Registration Document Filing

Universal Registration Document OSE Immunotherapeutics Cash Runway 2025 Financial Results IRIS Financing
BRIEF

published on 06/03/2026 at 20:24, 3 months 7 days ago

OSE Immunotherapeutics publie ses résultats financiers pour 2025 et dépose son document d'enregistrement universel.

Document D'Enregistrement Universel Cash Runway Résultats Financiers 2025 Immunothérapies OSE Financement IRIS
PRESS RELEASE

published on 06/03/2026 at 20:19, 3 months 7 days ago

OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
OSE Immunotherapeutics reports full year 2025 audited consolidated financial results and filing of 2025 Universal Registration Document, confirming cash runway with IRIS Financing

Universal Registration Document OSE Immunotherapeutics Cash Runway 2025 Financial Results IRIS Financing
PRESS RELEASE

published on 06/03/2026 at 20:19, 3 months 7 days ago

OSE Immunotherapeutics publie ses résultats financiers consolidés audités pour l’exercice 2025 et annonce le dépôt de son Document d’Enregistrement Universel 2025
OSE Immunotherapeutics publie ses résultats financiers consolidés audités pour l’exercice 2025 et annonce le dépôt de son Document d’Enregistrement Universel 2025

Résultats Financiers Trésorerie Document D’enregistrement Universel OSE Immunotherapeutics Audités
BRIEF

published on 05/28/2026 at 21:09, 3 months 13 days ago

OSE Immunotherapeutics Secures Flexible Bridge Equity Financing

Strategic Plan Clinical Development Institutional Investors Share Issuance Flexible Financing
BRIEF

published on 05/28/2026 at 21:09, 3 months 13 days ago

OSE Immunotherapeutics obtient un financement relais flexible en fonds propres

Plan Stratégique Investisseurs Institutionnels Développement Clinique Émission D'actions Financement Flexible

Accesswire

Published on 09/11/2026 at 04:00, 7 hours 6 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 12 hours 41 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 17 hours 20 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 19 hours 46 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 20 hours 6 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 10:15, 51 minutes ago

TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 09:20, 1 hour 46 minutes ago

Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 2 hours 1 minute ago

ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 2 hours 6 minutes ago

Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 09:00, 2 hours 6 minutes ago

Picton Property Income Limited - Removal

Les Echos

Published on 09/11/2026 at 07:00, 4 hours 6 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 4 hours 6 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 4 hours 6 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 4 hours 6 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 15 hours 36 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE